Currently Viewing:
The International Society for Pharmacoeconomics and Outcomes Research
Continuing Forward With Innovation and Progress in US Healthcare
May 22, 2017
Dr Gail Wilensky: Senate Health Bill Will Be to the Left of the House
May 22, 2017
Accounting for Stakeholder Preferences in Value Assessments
May 22, 2017
Dr David M. Cutler Highlights the Importance of Reauthorizing the CHIP Program
May 22, 2017
Negotiating Successful Outcomes-Based Contracts
May 23, 2017
Dr Ilene Hollin: Tailored Approach to Value Assessment Is Necessary
May 23, 2017
Influencing Untreated Individuals Through Their Social Networks
May 23, 2017
Currently Reading
Dr Steve Pearson Outlines the Importance of Thresholds on Determining Value
May 23, 2017
Dr Patricia Danzon: Cost-Effectiveness Thresholds Create Incentive to Develop Better Drugs
May 24, 2017
Gene Therapies Present Great Potential, but Also Ethical and Practicality Challenges
May 24, 2017
Dr James D. Chambers Talks Future Health Economics Trends He Is Watching
May 24, 2017
Dr Gail Wilensky Remains "Hopeful" for Bipartisan Legislation on Healthcare Reform
May 29, 2017
Dr David Cutler: Won't Be Easy for Senate Republicans to Create a Healthcare Bill
May 30, 2017
Not Enough Attention Paid to Low Healthcare Spending Growth
June 13, 2017
Dr Steve Pearson's Outlook on the Ongoing Updates to ICER's Value Framework
June 18, 2017
Dr Scott Ramsey on Challenges of Determining Cost Effectiveness of Novel Cancer Treatments
June 19, 2017
Dr David Cutler Discusses Opportunities for Bipartisan ACA Reform
June 20, 2017
Dr Steve Pearson Explains How ICER Price Benchmarks Align Cost With Patient Benefits
June 22, 2017
Dr Gail Wilensky Raises Questions About Medicaid's Matching Grant Structure
June 25, 2017
Dr Scott Ramsey Addresses the Need for Differential Pricing Structures for Drugs
July 02, 2017
Dr Steve Pearson: Patient Perspectives Guide ICER Value Framework Development
July 04, 2017
Dr Gail Wilensky on the Likelihood of Continuing Value-Based Reimbursement Demonstrations
July 06, 2017
Dr David Cutler: Trump Administration's Attention Not on Value-Based Purchasing
July 09, 2017
Dr Steve Pearson on Data Needed to Evaluate Clinical and Economic Effects of New Therapies
July 14, 2017

Dr Steve Pearson Outlines the Importance of Thresholds on Determining Value

Thresholds can be useful to focus the conversation around the value of treatments in healthcare even if stakeholders have different views on what thresholds should be, explained Steve Pearson, MD, MSc, president of the Institute for Clinical and Economic Review.


Thresholds can be useful to focus the conversation around the value of treatments in healthcare even if stakeholders have different views on what thresholds should be, explained Steve Pearson, MD, MSc, president of the Institute for Clinical and Economic Review.

Transcript

What is the importance of utilizing thresholds to judge affordability and value?

Thresholds mean different things to different people. I think the value of a threshold in itself is that it helps focus the conversation. And it does help to, in a sense, put a stake in the sand, to say, 'This is one way of thinking about how much more we should be willing to pay for an added clinical benefit to patients.' You can always let decision makers judge that or themselves.

And in a very pluralistic health system like the US, you might assume that some payers or some health systems, even some consumers or patients, have different thresholds for what they are willing to pay or how they would like to allocate their resources. But having one theshold, in a sense, helps treat, different conditions fairly or similarly across those different conditions. Because intuitively, there's no reason why we should automatically assumed we should pay more for a patient in heart disease than a patient with a neurologic disorder, or vice versa.

So thresholds kind of throw that conversation fairly across all treatment areas. And also if you're looking at drugs or devices or different kinds of changes to the healthcare system, it puts those on the same playing field, as well. So it's not by itself a definitive answer that you just kind of write down and people walk away. But it's a way to stimulate and focus the kinds of conversation about value that we want to have with all stakeholders at the table.

 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up